107 related articles for article (PubMed ID: 36549117)
21. Drugging MYCN through an allosteric transition in Aurora kinase A.
Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
23. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
[TBL] [Abstract][Full Text] [Related]
24. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells.
Yang Y; Ding L; Zhou Q; Fen L; Cao Y; Sun J; Zhou X; Liu A
Cancer Cell Int; 2020; 20():9. PubMed ID: 31920463
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
Calero R; Morchon E; Johnsen JI; Serrano R
PLoS One; 2014; 9(4):e95628. PubMed ID: 24759734
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of a covalently linked Aurora-A-MYCN complex.
Diebold M; Schönemann L; Eilers M; Sotriffer C; Schindelin H
Acta Crystallogr D Struct Biol; 2023 Jan; 79(Pt 1):1-9. PubMed ID: 36601802
[TBL] [Abstract][Full Text] [Related]
27. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
28. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
29. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
30. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH
EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271
[TBL] [Abstract][Full Text] [Related]
31. The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ; Zhuo R; Zhang ZM; Yang Y; Tao YF; Wang JW; Li XL; Xie Y; Li G; Wu D; Chen YL; Yu JJ; Feng CX; Li ZH; Zhou RF; Yang RD; Yang PC; Zhou B; Wan XM; Wu YM; Jiao WY; Zhou NN; Fang F; Pan J
J Immunol Res; 2022; 2022():7945884. PubMed ID: 36438198
[TBL] [Abstract][Full Text] [Related]
32. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
[TBL] [Abstract][Full Text] [Related]
33. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
[TBL] [Abstract][Full Text] [Related]
34. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
Schnepp RW; Khurana P; Attiyeh EF; Raman P; Chodosh SE; Oldridge DA; Gagliardi ME; Conkrite KL; Asgharzadeh S; Seeger RC; Madison BB; Rustgi AK; Maris JM; Diskin SJ
Cancer Cell; 2015 Nov; 28(5):599-609. PubMed ID: 26481147
[TBL] [Abstract][Full Text] [Related]
35. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
36. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
37. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase.
Adhikari B; Bozilovic J; Diebold M; Schwarz JD; Hofstetter J; Schröder M; Wanior M; Narain A; Vogt M; Dudvarski Stankovic N; Baluapuri A; Schönemann L; Eing L; Bhandare P; Kuster B; Schlosser A; Heinzlmeir S; Sotriffer C; Knapp S; Wolf E
Nat Chem Biol; 2020 Nov; 16(11):1179-1188. PubMed ID: 32989298
[TBL] [Abstract][Full Text] [Related]
38. BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
Zhang X; Guo X; Zhuo R; Tao Y; Liang W; Yang R; Chen Y; Cao H; Jia S; Yu J; Liao X; Li X; Fang F; Li G; Wu D; Xu Y; Li Z; Pan J; Wang J
Biochem Biophys Res Commun; 2022 May; 604():63-69. PubMed ID: 35299072
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
[TBL] [Abstract][Full Text] [Related]
40. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
